Related references
Note: Only part of the references are listed.No Reduction in Circulating Preosteoclasts 18 Months after Treatment with Zoledronate: Analysis from a Randomized Placebo Controlled Trial
Nicola Dalbeth et al.
CALCIFIED TISSUE INTERNATIONAL (2013)
Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases
Junichi Kikuta et al.
RHEUMATOLOGY (2013)
The three human monocyte subsets: implications for health and disease
Kok Loon Wong et al.
IMMUNOLOGIC RESEARCH (2012)
CD16 (FcR gamma III) as a potential marker of osteoclast precursors in psoriatic arthritis
Yahui Grace Chiu et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6
Huang Hongming et al.
LEUKEMIA RESEARCH (2009)
Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women
Patrizia D. Amelio et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Myeloma bone disease: Pathogenetic mechanisms and clinical assessment
Franco Silvestris et al.
LEUKEMIA RESEARCH (2007)
Bone markers in multiple myeloma
Ulrike Heider et al.
EUROPEAN JOURNAL OF CANCER (2006)
Characterization of osteoclast precursors in human blood
V Shalhoub et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Share Paper
